Circadin ‐ a prolonged‐release formulation containing 2mg melatonin ‐ offers a promising short‐term treatment for primary insomnia that is characterised by poor sleep quality in patients aged 55 years or over. Medical writer, Mark Greener, reviews this new addition to the sleep treatment armamentarium. Copyright © 2008 Wiley Interface Ltd